The most frequently targeted CIS targets displaying strong evidence of enhancer mode activation included Otx2, a homeobox transcription factor which plays a major oncogenic role in medulloblastoma [32] but has not previously been observed in haematopoietic cancers and Myo16, an atypical nuclear myosin with links to survival, cell cycle progression and PI3K signalling [33]. This evidence concerns the gene MYO16 and in situ carcinoma.